Data demonstrated that a single oral dose of D-4517.2 significantly reduced choroidal neovascularization (CNV) lesions to a level comparable to D-4517.2 delivered subcutaneously and Aflibercept
Data demonstrated D-4559 switches tumor associated macrophages from an M2 to M1 pro-inflammatory phenotype leading to reduction in tumor growth in a mouse model of
Preclinical data to be presented at AACR will showcase the potential effect of D-4559, a potent macrophage switching nanomedicine, on reducing tumor growth in a
– The study will evaluate the safety, tolerability and ability of [18F]OP-801 to cross the blood brain barrier and selectively target neuroinflammation in individuals with
REDWOOD CITY, Calif., February 2, 2023 – Ashvattha Therapeutics (“Ashvattha”), a clinical-stage company leveraging its nanomedicine technology, hydroxyl dendrimers (HDs), to develop a new class
REDWOOD CITY, Calif., January 3, 2023 – Ashvattha Therapeutics (“Ashvattha”), a clinical-stage company leveraging its nanomedicine technology, hydroxyl dendrimers (HDs), to develop a new class
REDWOOD CITY, Calif., October 20, 2022 – Ashvattha Therapeutics (“Ashvattha”), a clinical-stage company developing novel hydroxyl dendrimer therapeutics (HDTs), today announced that Steve Maricich, M.D.,
– Data demonstrated [18F]OP-801 is a promising tracer for imaging activated macrophages/microglia with high sensitivity in the lumbar spine of a murine model of multiple
– Scientific collaborators at Stanford University will present data on an imaging and treatment regimen demonstrating the microglial targeting of [18F]OP-801 in a mouse model
– First patient was enrolled as part of a two-stage Phase 2 study evaluating Ashvattha’s subcutaneous (SC) anti-VEGF wet AMD and DME candidate, D-4517.2 –